beta

ADMP

Adamis Pharmaceuticals Corp

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The company's SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis' naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose is currently under FDA review. Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, influenza, asthma, and COPD. The company's subsidiary, US Compounding Inc., compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States. Forward Looking Statements

Market Cap: 156 Million

Primary Exchange: NASDAQ

Website: www.adamispharmaceuticals.com

Shares Outstanding: 149 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.34523486012793

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 2288 trading days

From: 2013-02-12 To: 2021-09-23

Lowest Point:

Adamis: Share Price Continues To Grind Down To A Fine Discount

via: SeekingAlpha at 2019-06-13 04:24:20:000

Adamis Pharmaceuticals ( ADMP ) is a specialty biopharmaceutical company dedicated to developing and commercializing various therapeutic products. The company's leading product, SYMJEPI, is a pre-filled syringe "PFS" device holding 0.3mg or 0.15mg dosage of epinephrine that has FDA approval fo… read more...

Adamis amends U.S. application for higher dose naloxone, hopes for speedy approval

via: SeekingAlpha at 2019-06-11 07:39:43:000

Based on FDA feedback, Adamis Pharmaceuticals ( ADMP -4.5% ) has removed kalo's EVZIO (naloxone HCl injection) 2 mg auto-injector as the Reference Listed Drug (RLD) in its marketing application seeking approval for its higher dose naloxone injection product for the emergency trea… read more...

Adamis amends U.S. application for higher dose naloxone, hopes for speedy approval

via: SeekingAlpha at 2019-06-11 07:39:43:000

Based on FDA feedback, Adamis Pharmaceuticals ( ADMP -4.5% ) has removed kalo's EVZIO (naloxone HCl injection) 2 mg auto-injector as the Reference Listed Drug (RLD) in its marketing application seeking approval for its higher dose naloxone injection product for the emergency trea… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
2013-12-13 17.0 1.0 17.0
Data provided by IEX Cloud